Cancer in Guatemala

IARC estimates 20,882 new cancer cases and 11,782 cancer deaths in Guatemala in 2024; the commonest new cancers are prostate, liver and intrahepatic bile ducts and breast. This page is assembled automatically from OnCo's data: 36 trials with a site there, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

20,882

all cancers

Deaths

11,782

all cancers

Incidence rate

149.3

per 100,000, age-standardised

Mortality rate

87.6

per 100,000, age-standardised

Cumulative risk

12.8%

of a cancer by age 74

Population

18,406,362

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	3,400	59.7	Prostate cancer
Liver and intrahepatic bile ducts	2,400	18.5	Hepatocellular carcinoma
Breast	2,075	26.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Cervix uteri	1,894	24.9	Cervical cancer
Stomach	1,739	12.5	Gastric & gastro-oesophageal junction cancer
Leukaemia	1,164	6.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Colorectum	1,089	7.9	Colorectal cancer
Trachea, bronchus and lung	794	5.9	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Thyroid	524	3.9	Thyroid cancer
Non-Hodgkin lymphoma	491	3.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Most deaths

Site	Deaths	Rate	OnCo page
Liver and intrahepatic bile ducts	2,289	17.7	Hepatocellular carcinoma
Stomach	1,441	10.8	Gastric & gastro-oesophageal junction cancer
Cervix uteri	1,108	15.0	Cervical cancer
Prostate	786	14.5	Prostate cancer
Leukaemia	746	4.6	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Trachea, bronchus and lung	720	5.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	648	8.8	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	613	4.6	Colorectal cancer
Pancreas	441	3.4	Pancreatic ductal adenocarcinoma
Brain, central nervous system	246	1.7	Glioma & glioblastoma

Incidence: method 3c, national mortality estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Guatemala”, in Central America (Latin America and the Caribbean), Medium HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

36 trials in OnCo · 7 recruiting overall

36 trials

Trial			Lead sponsor
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
waveLINE-003 NCT05139017	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	135	2026-10-06
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi NCT06717347	Phase 3	Recruiting	Merck Sharp & Dohme LLC	278	2026-09-25
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan NCT04956692	Phase 3	Completed	Merck Sharp & Dohme LLC	126	2026-10-07
LITESPARK-012 NCT04736706	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	262	2026-10-02
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	93	2026-10-02
HERIZON-GEA-01 NCT05152147	Phase 3	Active not recruiting	Jazz Pharmaceuticals	227	2026-09-24
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) NCT06065748	Phase 3	Active not recruiting	Hoffmann-La Roche	311	2026-09-14
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612	Phase 2	Active not recruiting	Genentech, Inc.	179	2026-08-28
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	110	2026-08-26
KEYNOTE-811 NCT03615326	Phase 3	Completed	Merck Sharp & Dohme LLC	192	2026-08-26
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) NCT03742895	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	130	2026-08-14
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063	Phase 3	Active not recruiting	Hoffmann-La Roche	80	2026-07-24
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) NCT04895358	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	256	2026-07-22
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) NCT06698042	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	67	2026-07-21
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) NCT04895722	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	109	2026-07-02
lidERA NCT04961996	Phase 3	Active not recruiting	Hoffmann-La Roche	622	2026-06-17
ALEX NCT02075840	Phase 3	Completed	Hoffmann-La Roche	97	2026-05-29
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) NCT03711032	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	209	2026-05-01
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	134	2026-05-01
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) NCT05624554	Phase 3	Active not recruiting	Merck Sharp & Dohme LLC	97	2026-03-16
KEYNOTE-859 NCT03675737	Phase 3	Completed	Merck Sharp & Dohme LLC	215	2026-02-27
KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 NCT04221945	Phase 3	Completed	Merck Sharp & Dohme LLC	176	2026-02-20
APHINITY NCT01358877	Phase 3	Completed	Hoffmann-La Roche	546	2025-11-28
KATHERINE NCT01772472	Phase 3	Completed	Hoffmann-La Roche	268	2025-07-22
KEYNOTE-590 NCT03189719	Phase 3	Completed	Merck Sharp & Dohme LLC	189	2024-10-15

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Guatemala, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Guatemala is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

OnCo holds no institution, company or person in Guatemala.

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Guatemala is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Guatemala's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Guatemala, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Guatemala's own sources.

Guatemala is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/gt.json; every country: /api/v1/countries.json.